BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shimose S, Iwamoto H, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Suga H, Kuromatsu R, Yamaguchi T, Kawaguchi T, Tanaka M, Noguchi K, Koga H, Torimura T. Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. Cancers (Basel) 2020;12:E1867. [PMID: 32664489 DOI: 10.3390/cancers12071867] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 13.5] [Reference Citation Analysis]
Number Citing Articles
1 Shimose S, Iwamoto H, Tanaka M, Niizeki T, Kajiwara M, Itano S, Moriyama E, Shirono T, Noda Y, Kamachi N, Nakano M, Kuromatsu R, Koga H, Kawaguchi T. Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study. Cancers 2022;14:4284. [DOI: 10.3390/cancers14174284] [Reference Citation Analysis]
2 Zhao L, Chang N, Shi L, Li F, Meng F, Xie X, Xu Z, Wang F. Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study. Heliyon 2022;8:e09538. [PMID: 35706954 DOI: 10.1016/j.heliyon.2022.e09538] [Reference Citation Analysis]
3 Ikesue H, Yamamoto H, Hirabatake M, Hashida T, Chung H, Inokuma T, Muroi N. Risk Factors of Proteinuria in Patients with Hepatocellular Carcinoma Receiving Lenvatinib. Biol Pharm Bull 2022;45:333-8. [PMID: 35228399 DOI: 10.1248/bpb.b21-00913] [Reference Citation Analysis]
4 Kinoshita A, Hagiwara N, Osawa A, Akasu T, Matsumoto Y, Ueda K, Saeki C, Oikawa T, Koike K, Saruta M. Poor tolerability of lenvatinib in elderly patients ≥80 years old with hepatocellular carcinoma: A multicenter observational study. J Oncol Pharm Pract 2022;:10781552221077039. [PMID: 35112972 DOI: 10.1177/10781552221077039] [Reference Citation Analysis]
5 Okubo H, Ando H, Ishizuka K, Morishige JI, Ikejima K, Shiina S, Nagahara A. Impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of lenvatinib in patients with hepatocellular carcinoma. J Pharmacol Sci 2022;148:6-13. [PMID: 34924131 DOI: 10.1016/j.jphs.2021.08.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Rimini M, Kudo M, Tada T, Shigeo S, Kang W, Suda G, Jefremow A, Burgio V, Iavarone M, Tortora R, Marra F, Lonardi S, Tamburini E, Piscaglia F, Masi G, Cabibbo G, Foschi FG, Silletta M, Kumada T, Iwamoto H, Aoki T, Goh MJ, Sakamoto N, Siebler J, Hiraoka A, Niizeki T, Ueshima K, Sho T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Tani J, Nakamura S, Nouso K, Tsutsui A, Nagano T, Takaaki T, Itokawa N, Okubo T, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y, Cucchetti A, Ratti F, Aldrighetti L, Cascinu S, Casadei-Gardini A. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib. ESMO Open 2021;6:100330. [PMID: 34847382 DOI: 10.1016/j.esmoop.2021.100330] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
7 Sun X, Yang Z, Tang Y, Mao S, Xiong P, Wang J, Chen J, Zhang Y, Chen M, Xu L. Optimal subsequent treatments for patients with hepatocellular carcinoma resistant to anti-PD-1 treatment. Immunotherapy 2021. [PMID: 34758630 DOI: 10.2217/imt-2021-0057] [Reference Citation Analysis]
8 Koroki K, Kanogawa N, Maruta S, Ogasawara S, Iino Y, Obu M, Okubo T, Itokawa N, Maeda T, Inoue M, Haga Y, Seki A, Okabe S, Koma Y, Azemoto R, Atsukawa M, Itobayashi E, Ito K, Sugiura N, Mizumoto H, Unozawa H, Iwanaga T, Sakuma T, Fujita N, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Saito T, Kondo T, Suzuki E, Ooka Y, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato J, Kato N. Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer 2021;10:473-84. [PMID: 34721509 DOI: 10.1159/000515552] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kim BH, Yu SJ, Kang W, Cho SB, Park SY, Kim SU, Kim DY. Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma. J Gastroenterol Hepatol 2021. [PMID: 34725855 DOI: 10.1111/jgh.15727] [Reference Citation Analysis]
10 Liu BJ, Gao S, Zhu X, Guo JH, Kou FX, Liu SX, Zhang X, Wang XD, Cao G, Chen H, Liu P, Xu HF, Gao QZ, Yang RJ. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma. Immunotherapy 2021;13:1395-405. [PMID: 34607482 DOI: 10.2217/imt-2021-0192] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
11 Yan Y, Qiao L, Hua Y, Shao S, Zhang N, Wu M, Liu L, Zhou K, Liu X, Wang C. Predictive value of Albumin-Bilirubin grade for intravenous immunoglobulin resistance in a large cohort of patients with Kawasaki disease: a prospective study. Pediatr Rheumatol Online J 2021;19:147. [PMID: 34563210 DOI: 10.1186/s12969-021-00638-7] [Reference Citation Analysis]
12 Ochi H, Tani J, Tomonari T, Taniguchi T, Koizumi Y, Hirose A, Ogawa C, Hiraoka A, Morishita A, Moriya A, Hirooka M, Deguchi A, Symple Study Group. Sequential therapy including regorafenib for unresectable hepatocellular carcinoma: Effect of early relative changes in hepatic functional reserve after regorafenib administration on prognosis. Hepatol Res 2021;51:1219-28. [PMID: 34534398 DOI: 10.1111/hepr.13713] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 Shimose S, Koya S, Kawaguchi T, Hirota K, Yoshio S, Niizeki T, Matsuse H, Torimura T. Impact of branched-chain amino acids and frailty on the management of lenvatinib-related fatigue in patients with hepatocellular carcinoma. Clin Mol Hepatol 2021;27:616-9. [PMID: 34517441 DOI: 10.3350/cmh.2021.0258] [Reference Citation Analysis]
14 Demirtas CO, D'Alessio A, Rimassa L, Sharma R, Pinato DJ. ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Rep 2021;3:100347. [PMID: 34505035 DOI: 10.1016/j.jhepr.2021.100347] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
15 Takahashi S. Fatigue and its management in cancer patients undergoing VEGFR-TKI therapy. Expert Opin Drug Saf 2021;:1-10. [PMID: 34461788 DOI: 10.1080/14740338.2021.1969360] [Reference Citation Analysis]
16 Makker V, Taylor MH, Oaknin A, Casado Herraez A, Orlowski R, Dutta L, Ren M, Zale M, O'Malley DM. Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab. Oncologist 2021;26:e1599-608. [PMID: 34190370 DOI: 10.1002/onco.13883] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
17 Catalano M, Casadei-Gardini A, Vannini G, Campani C, Marra F, Mini E, Roviello G. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma. Expert Rev Clin Pharmacol 2021;:1-13. [PMID: 34289756 DOI: 10.1080/17512433.2021.1958674] [Reference Citation Analysis]
18 Rapposelli IG, Tada T, Shimose S, Burgio V, Kumada T, Iwamoto H, Hiraoka A, Niizeki T, Atsukawa M, Koga H, Hirooka M, Torimura T, Iavarone M, Tortora R, Campani C, Lonardi S, Tamburini E, Piscaglia F, Masi G, Cabibbo G, Giuseppe Foschi F, Silletta M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Tani J, Nakamura S, Nouso K, Tsutsui A, Nagano T, Tanaka T, Itokawa N, Okubo T, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y, Rimini M, Ratti F, Aldrighetti L, Cascinu S, Casadei-Gardini A. Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. Liver Int 2021;41:2997-3008. [PMID: 34250737 DOI: 10.1111/liv.15014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
19 Sugimoto R, Inada H, Tanaka Y, Senju T, Aratake Y, Nakanishi A, Miki M, Lee L, Hisano T, Matsumoto Y, Mano Y, Iguchi T, Sugimachi K, Okumura Y, Taguchi K, Furukawa M. Improved indocyanine green retention after short-term lenvatinib withdrawal in three patients with hepatocellular carcinoma. Clin J Gastroenterol 2021. [PMID: 34176067 DOI: 10.1007/s12328-021-01470-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Iwamoto H, Shimose S, Noda Y, Shirono T, Niizeki T, Nakano M, Okamura S, Kamachi N, Suzuki H, Sakai M, Kajiwara A, Itano S, Tanaka M, Yamaguchi T, Kuromatsu R, Koga H, Torimura T, On Behalf Of The Kurume Liver Cancer Study Group Of Japan. Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. Cancers (Basel) 2021;13:2786. [PMID: 34205099 DOI: 10.3390/cancers13112786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
21 Ehret C, Jatoi A. Should Loss of Appetite Be Palliated in Patients with Advanced Cancer? Curr Treat Options Oncol 2021;22:31. [PMID: 33641020 DOI: 10.1007/s11864-021-00829-0] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
22 Goh MJ, Oh JH, Park Y, Kim J, Kang W, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea. Liver Cancer 2021;10:52-62. [PMID: 33708639 DOI: 10.1159/000512239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
23 Hatanaka T, Naganuma A, Kakizaki S. Lenvatinib for Hepatocellular Carcinoma: A Literature Review. Pharmaceuticals (Basel) 2021;14:36. [PMID: 33418941 DOI: 10.3390/ph14010036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
24 Shimose S, Iwamoto H, Tanaka M, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Suga H, Yamaguchi T, Kawaguchi T, Kuromatsu R, Noguchi K, Koga H, Torimura T. Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study. Cancers (Basel) 2021;13:E160. [PMID: 33466496 DOI: 10.3390/cancers13010160] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
25 Perera S, Kelly D, O'Kane GM. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease. Curr Oncol 2020;27:S165-72. [PMID: 33343210 DOI: 10.3747/co.27.7159] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
26 Wang Y, Jiang M, Zhu J, Qu J, Qin K, Zhao D, Wang L, Dong L, Zhang X. The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma. Biomed Pharmacother 2020;132:110797. [PMID: 33068935 DOI: 10.1016/j.biopha.2020.110797] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
27 Azuma S, Uojima H, Chuma M, Shao X, Hidaka H, Nakazawa T, Kondo M, Numata K, Iwabuchi S, Kako M, Maeda S, Koizumi W, Atsuda K. Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib. Sci Rep 2020;10:17054. [PMID: 33051476 DOI: 10.1038/s41598-020-73930-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]